XMD8-92, via inhibition of BMK1 activation, significantly induces p21 expression in cells, and mediates suppression of cancer cell proliferation. XMD8-92 markedly abrogates the inhibitive effects of hydroxysafflor yellow A (HSYA) on hepatic stellate cell (HSC) activation, and blockes the HSYA-mediated MEF2C down-regulation.
|Cell lines||A549 cell lines|
|Preparation method||Control and shBNIP3/shBNIP3L A549 sphere cells were treated with/without 4 μmol/L XMD8-92 for 36 hrs, and collected by trypsinization and centrifugation at 300 G for 5 mins. The resultant cells were washed twice with cold PBS and resuspended in 100 μL Annexin-binding buffer.|
|Incubation time||36 h|
|Animal models||Nod/Scid mice bearing HeLa xenograft, C57Bl/6 mice bearing LL/2 xenograft|
|Dosages||~50 mg/kg twice a day|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||73 mg/mL warmed in DMSO|
BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
Park SJ, et al. Cancer Lett. 2016 Oct 28;381(2):314-22. PMID: 27543359.
Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L.
Song C, et al. Oncotarget. 2015 Oct 20;6(32):33279-89. PMID: 26432836.
XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
Sureban SM, et al. Cancer Lett. 2014 Aug 28;351(1):151-61. PMID: 24880079.
|Related ERK Products|
VRT752271 (BVD-523, Ulixertinib) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ∼0.5 μM.
XMD17-109 is a novel, specific inhibitor of ERK-5 with an EC50 value of 4.2 μM in HEK293 cells.
GDC-0994 is a potent, orally available ERK inhibitor with IC50 1.1 nM and 0.3 nM, respectively.
FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.